← Back to Search

Aerobic Exercise for Schizophrenia

N/A

Waitlist Available

Led By David Kimhy, PhD

Research Sponsored by Icahn School of Medicine at Mount Sinai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 12 weeks

Awards & highlights

Study Summary

This trial will test the impact of exercise on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.

Eligible Conditions

Schizophrenia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Body Weight Changes

Change in the MATRICS Consensus Cognitive Battery (MCCB)

Secondary outcome measures

Change in Columbia Suicide Severity Rating Scale (C-SSRS)

Change in the Schizophrenia Cognition Rating Scale (SCoRS)

Change in the Specific Levels of Functioning Scale (SLOF)

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Aerobic ExerciseExperimental Treatment1 Intervention

Using trainer-led video calls with traditional callisthenic body movements (e.g., jumping jacks, burpees, etc.)

Group II: Stretching and Toning ExerciseActive Control1 Intervention

Using trainer-led video calls with stretching and toning exercises.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Aerobic Exercise

2013

Completed Early Phase 1

~1310

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityOTHER

2,386 Previous Clinical Trials

17,333,904 Total Patients Enrolled

7 Trials studying Schizophrenia

236 Patients Enrolled for Schizophrenia

University of North Carolina, Chapel HillOTHER

1,504 Previous Clinical Trials

4,187,558 Total Patients Enrolled

26 Trials studying Schizophrenia

2,555 Patients Enrolled for Schizophrenia

Icahn School of Medicine at Mount SinaiLead Sponsor

858 Previous Clinical Trials

524,182 Total Patients Enrolled

6 Trials studying Schizophrenia

397 Patients Enrolled for Schizophrenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for individuals to participate in this experiment?

"According to clinicaltrials.gov, the original posting for this trial was on April 26th 2018 and it has not been updated since October 3rd 2022. Although no longer seeking participants, there are 334 other trials actively recruiting at present."

Answered by AI

In what states is the study being conducted?

"The medical trial is currently recruiting patients at Icahn School of Medicine at Mount Sinai in New york, Augusta University in Augusta, and University of North carolina in Chapel Hill. Additionally, there are 4 other sites that are participating as well."

Answered by AI

Is the age qualification for this research project limited to individuals over 35 years old?

"Those aged 18 to 55 are the only ones eligible for this trial; conversely, there exist 46 trials for minors and 165 studies catering to individuals over 65."

Answered by AI

What are the prerequisites for joining this clinical experiment?

"This clinical trial is accepting 200 applicants with a diagnosis of schizophrenia, aged between 18 and 55."

Answered by AI

What are the desired results of this medical experiment?

"The main goal of this trial, which shall be monitored over a 12 week period and compared to baseline results is an improvement in the MATRICS Consensus Cognitive Battery (MCCB). Supplementary objectives include tracking changes in serum BDNF levels as well as measuring improvements on the Columbia Suicide Severity Rating Scale (C-SSRS) and UCSD Performance-based Skills Assessment (UPSA), both ranging from 1 to 10 or 0 to 100 respectively."

Answered by AI

Recent research and studies

Schizophrenia ResearchJournal

Aerobic Exercise for Cognitive Deficits in Schizophrenia — the Impact of Frequency, Duration, and Fidelity with Target Training Intensity

Kimhy, David, Vincenzo Lauriola, Matthew N. Bartels, Hilary F. Armstrong, Julia Vakhrusheva, Jacob S. Ballon, and Richard P. Sloan. 2016. “Aerobic Exercise for Cognitive Deficits in Schizophrenia — the Impact of Frequency, Duration, and Fidelity with Target Training Intensity”. Schizophrenia Research. Elsevier BV. doi:10.1016/j.schres.2016.01.055.

TrialsJournal

Suicide Reduction in Schizophrenia via Exercise (sunrise): Study Protocol for a Multi-site, Single-blind, Randomized Clinical Trial of Aerobic Exercise for Suicide Risk Reduction in Individuals with Schizophrenia

Beck-Felts, Katie, Marianne Goodman, Luz H. Ospina, Melanie Wall, Joseph McEvoy, Lars F. Jarskog, Jacob S. Ballon, et al.. 2020. “Suicide Reduction in Schizophrenia via Exercise (sunrise): Study Protocol for a Multi-site, Single-blind, Randomized Clinical Trial of Aerobic Exercise for Suicide Risk Reduction in Individuals with Schizophrenia”. Trials. Springer Science and Business Media LLC. doi:10.1186/s13063-020-04788-z.

Schizophrenia BulletinJournal

The Impact of Aerobic Exercise on Brain-derived Neurotrophic Factor and Neurocognition in Individuals with Schizophrenia: A Single-blind, Randomized Clinical Trial

Kimhy, David, Julia Vakhrusheva, Matthew N. Bartels, Hilary F. Armstrong, Jacob S. Ballon, Samira Khan, Rachel W. Chang, et al.. 2015. “The Impact of Aerobic Exercise on Brain-derived Neurotrophic Factor and Neurocognition in Individuals with Schizophrenia: A Single-blind, Randomized Clinical Trial”. Schizophrenia Bulletin. Oxford University Press (OUP). doi:10.1093/schbul/sbv022.

Current Behavioral Neuroscience ReportsJournal